| 摘要 |
<p>The present disclosure relates to methods for detecting specific metabolites that are indicative of cancer via nuclear magnetic resonance (NMR) or magnetic resonance imaging (MRI). In certain embodiments, the method enables detection of 2 -hydroxy glutarate (2HG) non-invasively in biospecimens or patients. 2HG is a metabolite produced at elevated levels by tumors that harbor mutations in the isocitrate dehydrogenase IDH genes 1 or 2. Certain embodiments of this method have clinical applicability in detecting and diagnosing human tumors that harbor mutations, such as mutations of IDHl or IDH2, and to predict prognosis and monitor post-treatment of those tumors.</p> |
